
So great to meet all of the residents at @AmerUrological #AUAFundamentals today and to discuss #KidneyCancer. My @michaelpollan inspired approach to kidney tumors:
✓Urologic Oncologist at NCI | Assoc Prof & Fellowship APD | #kidneycancer #pheo surgery & translational genomics 🧬 Views mine

So great to meet all of the residents at @AmerUrological #AUAFundamentals today and to discuss #KidneyCancer. My @michaelpollan inspired approach to kidney tumors:

And a mini @brady_urology reunion! @nirmishsingla @markballmd @PeterPintoMD @allaf_mo

Dr. @markballmd of @theNCI reviews current approaches to papillary RCC, including PAPMET, KEYNOTE-B61 and phase 2 cabozantinib + nivolumab data, while highlighting molecular subtyping and MET-directed precision oncology as evolving strategies. CALYPSO: cRR was 32% overall and 53% in MET-driven papillary RCC; no new safety signals. #DAVAGU

Starting Soon: Advances in HIF Inhibitors in Advanced RCC Moderator: Dr. Mark Ball @markballmd @theNCI The session will explore belzutifan data (LITESPARK-011/033), emerging HIF-2α therapies & novel combination strategies in RCC. #DAVAGU

With HLRCC, finding kidney tumors early matters. Yearly kidney imaging from age 8, often MRI, is recommended for people with or at risk of HLRCC. Ask your doctor what's right for you. Thanks to @markballmd and NCI for their work. Specialists: hlrcc.org/hlrcc-map/ #HLRCC

Surgery or belzutifan in VHL? Dr. @markballmd (@theNCI) weighs serial partial nephrectomy morbidity against LITESPARK-004 ORRs (RCC 67%, CNS HB 48%, pNET 91%) and discusses when tumorgrowth on belzutifan may warrant surgery. #DAVAGU

⚡️ On @EUplatinum 25-yr prospective NCI cohort of sporadic bilateral multifocal papillary RCC (n=89). Growth was predominantly indolent (median 1.55 mm/yr). Metastases occurred only in patients whose largest tumor exceeded 3 cm. Repeat ipsilateral partial nephrectomy was associated with a decline in renal function. Findings are consistent with active surveillance for small renal masses and nephron-sparing surgery when intervention is needed. #KidneyCancer sciencedirect.com/science/ar…

🔬 What is the natural history of sporadic bilateral/multifocal papillary #RCC? A 25-year prospective @theNCI 📈 Median growth: only 1.55 mm/year ⚠️ Metastases occurred in 6.7% — exclusively when the largest tumor was >3 cm 💡 These data provide important benchmarks supporting active surveillance for appropriately selected small tumors and nephron-sparing approaches when intervention is needed. Congratulations to the authors for advancing our understanding of this uncommon clinical entity! 📖 Read here: doi.org/10.1016/j.euo.2026.0… @HFu_MD @markballmd @SandeepGurramMD @montypal @kidneycan

Also a big shout-out to the @theNCI Urologic Oncology (SUO) fellowship 🙌 The fellowship gives us a platform not just to sharpen our operating, but to rethink GU cancer as a biology and a disease process. It also trains us to make careful, multidisciplinary decisions for every patient. NCI is a remarkable place to learn to think as a surgeon-scientist. Our clinical year has been just as rewarding. We now rotate at Walter Reed, Sibley, GW, and MedStar Washington Hospital Center, which gives us broad exposure across the DC area. Interested Applicants feel free to DM with questions! @PeterPintoMD @markballmd @patmichael93 @ztonysu @Moh_AhmedMD @Anis_Assad10 @RubenBlachmanMD @SUO_YUO @UroOnc #SUO #YUO #UroSoMe

Great talk by @SandeepGurramMD of the NCI Urologic Oncology Branch (@nciccr_gmb @NCICCR_SurgOnc @theNCI) on penicillin, parachutes, and when "isn't it obvious?" is not good enough. Big effects rarely need a trial. Most of organ-sparing therapy is not a parachute. @FocalSociety @Endo_Society @SocietySURS #urology #prostatecancer

Grateful for the chance to work on this unique project and share our experience. Big shout-out to the @theNCI @SUO_YUO @UroOnc fellowship — outstanding mentors, co-fellows, supportive staff, and a great city. Doing science and having fun. 🙌 @markballmd

New paper out in @EurUrolOncol! 🧬 We present the largest prospective cohort of sporadic bilateral/multifocal papillary RCC (89 patients, 25 years at the NCI). Key findings: 📉 Slow, indolent growth (median 1.55 mm/yr) 🎯 No metastases when largest tumor <3cm 🔬 Low metastatic rate overall (6.7%) 🩺 Repeat ipsilateral partial nephrectomy = biggest hit to kidney function Supports active surveillance for small renal masses + nephron-sparing surgery when intervention is needed. @markballmd @RubenBlachmanMD @MillanBraden @patmichael93 Natural History, Tumor Growth Kinetics, and Renal Functional Outcomes... sciencedirect.com/science/ar…

Thanks for sharing. Proud to finally show data to support the practice we have followed for a long time. @SUO_YUO fellow @HFu_MD put this together. Even when surgery is the the next step, my first ? is what life events do you have coming up - weddings, trips, etc. SRMs ≠ emergencies. @EurUrolOncol

📅 New #Article in #Vol33_Iss8 📑 "Completion Nephrectomy Outcomes Following Prior Partial Nephrectomy in Hereditary Kidney Cancer Syndromes" ✍️ by Patrick D. Michael et al. 📍 Access the full paper here: brnw.ch/21x4LQY #HereditaryKidneyCancer #CompletionNephrectomy

📢We are pleased to announce that our 2025 IF is 2.8! We extend our sincere gratitude to all authors, reviewers, readers, and members of the editorial team for their invaluable contributions and continued support! #impactfactor @SUO_YUO @UroOnc @ElsevierConnect

If pathology influences how we operate, shouldn't we know it before or during surgery? Renal mass biopsy remains underutilized. We explored whether AI can predict final pathology from intraoperative gross tumor images. Early results are encouraging, and we're just getting started. Led by #MilanPatel. sciencedirect.com/science/ar…